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Abstract
Background: Viscum album (VA) preparations have been used as a complimentary therapy in
cancer. In addition to their cytotoxic properties, they have also been shown to have
immunostimulatory properties. In the present study, we examine the hypothesis that the VA
preparations induce activation of human DC that facilitates effective tumor regression.
Methods: Four day old monocyte-derived immature DCs were treated with VA Qu Spez at 5, 10
and 15 μg/ml for 48 hrs. The expression of surface molecules was analyzed by flow cytometry. The
ability of Qu Spez-educated DC to stimulate T cells was analyzed by allogeneic mixed lymphocyte
reaction and activation of Melan-A/MART-1-specific M77-80 CD8+T cells. Cytokines in cell free
culture supernatant was analyzed by cytokine bead array assay.
Results: VA Qu Spez stimulated DCs presented with increased expression of antigen presenting
molecule HLA-DR and of co-stimulatory molecules CD40, CD80 and CD86. The VA Qu Spez also
induced the secretion of inflammatory cytokines IL-6 and IL-8. Further, Qu Spez-educated DC
stimulated CD4+T cells in a allogeneic mixed lymphocyte reaction and activated melanoma antigen
Melan-A/MART-1-specific M77-80 CD8+T cells as evidenced by increased secretion of TNF-α and
IFNγ.
Conclusion: The VA preparations stimulate the maturation and activation of human DCs, which
may facilitate anti-tumoral immune responses. These results should assist in understanding the
immunostimulatory properties of VA preparations and improving the therapeutic strategies.
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Background
VA preparations are aqueous extracts from Viscum album
(also known as European mistletoe) consisting of differ-
ent types of lectins [1-3]. In addition to mistletoe lectins
(ML), biologically active components of VA preparations
include viscotoxins, several enzymes, peptides (such as
viscumamide), amino acids, thiols, amines, polysaccha-
rides, cyclitoles, lipids, phytosterols, triterpines, flavo-
noids, phenylpropanes and minerals [3,4]. VA
preparations have been used as a complimentary therapy
in cancer. Several studies have reported the clinical bene-
fits of VA preparations in cancer patients [5,6]. Treatment
with VA preparations or purified ML has also been shown
to be associated with tumor regression in several experi-
mental models [7,8]. The mechanisms underlying the
anti-tumoral activity of VA preparations are complex and
not completely understood. The proposed mechanisms
include induction of apoptosis of tumor cells and lym-
phocytes, inhibition of angiogenesis and stimulation of
the cellular compartment of the immune system [9-14].
During the course of tumor development, the tumor
evades the immune system through the secretion of vari-
ous factors such as VEGF, IL-10 and PGE2 that have been
shown to inactivate the immune system [15]. The differ-
ent pathways of immune evasion by tumors involve:
induction of immune tolerance, resistance to killing by
immune effector cells, and imparting functional paralysis
of professional antigen presenting cells (APCs) such as
dendritic cells (DCs) [15].
DCs are the professional APCs that are specialized in the
uptake of antigens and their transport from peripheral tis-
sues to the lymphoid organs [16,17]. Because of their
capacity to stimulate naive T cells, DCs have a central role
in the initiation of primary immune responses [18]. DCs
reside in periphery as immature cells with a high ability to
endocytose target antigens [19]. Upon receiving appropri-
ate stimuli and in the context of inflammation, DCs
undergo maturation process characterized by increased
surface expression of antigen presenting HLA molecules
and co-stimulatory molecules such as CD80 and CD86
and secrete several pro-inflammatory cytokines [20].
Tumor cells suppress the maturation and activation proc-
ess of DCs [21]. Thus, several studies have demonstrated
that DCs that reside in the tumor site or in the vicinity of
tumor are immature with a decreased ability to stimulate
T cells [22,23]. In addition, tumor cells secrete several
anti-inflammatory cytokines such as IL-10 and TGF,
which can suppress the functions of DCs [24-26]. In view
of the anti-tumoral and immunostimulatory properties of
VA preparations, and the central role of DCs in anti-
tumoral immune response, we examined the hypothesis
that VA preparations stimulate the DCs, which in part
explains the mechanisms underlying the beneficial effect
of VA preparations in cancer therapy.
Methods
Antibodies and reagents
Recombinant human (rh) interleukin-4 (IL-4) was
obtained from R&D Systems (Lille, France), and rh granu-
locyte macrophage-colony-stimulating factor (rh GM-
CSF), rhIL-2 and rhTNFα were obtained from Immunoto-
ols (Friesoythe, Germany). FITC-conjugated monoclonal
antibodies (mAb) to HLA-DR and CD80, PE-conjugated
mAbs to CD86, CD40 and CD83 and APC-conjugated
mAbs to CD11c were obtained from BD biosciences
(France).
VA preparations
VA Qu Spez, was a kind gift from Weleda AG (Arlesheim,
Switzerland). VA Qu Spez is the extract of Viscum album
growing on oak trees. The VA preparations are therapeutic
preparations that are free from endotoxins. VA prepara-
tions are formulated in sodium chloride (NaCl 0.9%) iso-
tonic solution as 5 mg/ml vials. During the manufacturing
process, VA preparations are prepared by standardizing
the levels of Mistletoe lectins and Viscotoxins. The con-
centrations of the lectins and viscotoxins of the different
preparations used in the study are summarized in Table 1.
Generation and culture of monocyte-derived human 
dendritic cells
Peripheral blood mononuclear cells (PBMC) were iso-
lated from buffy coats of healthy donors purchased from
Hopital Hotel Dieu, Etablissement Français du Sang (06/
EFS/029, dated 29.05.2006), upon ethical approval for
the use of such materials. The percentage of monocytes in
the PBMC preparations was in the range of 9 to 14%.
Monocytes were positively isolated using CD14 beads
(Miltenyi Biotec, France). The purity of the monocytes
after purification is > 98%. Immature DCs were generated
by culturing monocytes for 4 days in RPMI 1640 contain-
Table 1: Concentrations of Mistletoe Lectins and Viscotoxins in VA Qu Spez
Preparation Concentration used (μg/ml) Lectin (ng/ml) Viscotoxin (ng/ml)
VA Qu Spez 5 0.375 0.012
VA Qu Spez 10 0.750 0.024
VA Qu Spez 15 1.125 0.036BMC Cancer 2008, 8:161 http://www.biomedcentral.com/1471-2407/8/161
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ing 10% FCS, 50 U/ml penicillin, 50 μg/ml streptomycin,
rhIL-4 (500 IU/106 cells), and rhGM-CSF (1000 IU/106
cells). Half of the medium, including all supplements,
was replaced on second day.
Analysis of the expression of surface molecules by flow 
cytometry
To investigate the effect of VA Qu Spez on DCs, 0.5 × 106
immature four-day old DCs were either untreated or
treated with TNFα (15 ng) or VA preparations (5, 10 and
15 μg) for 48 h. On day 6, cell surface staining was per-
formed with specifically labeled mAbs and proceeded for
flow-cytometry (LSR II, BD Biosciences, France). Ten
thousand events were recorded and analyzed for each
sample. Data were analyzed by BD FACSDIVA software
(BD Biosciences, France).
Mixed lymphocyte reaction (MLR) with allogenic CD4+ T 
cells
Responder CD4+ T cells used for allogeneic MLR assays
were isolated from PBMC of healthy donors using a nega-
tive isolation kit (Dynal biotech-Invitrogen, France). DCs
following 48 hr treatment with VA Qu Spez were washed
extensively and were seeded with 1 × 105 responder allo-
geneic T cells at DC:T cell ratios of 1:10, 1:20 and 1:40.
After 4 days, the cells were pulsed for 16 h with 0.5 μCi
(0.037 MBq) of (3H)thymidine. Radioactive incorpora-
tion was measured by standard liquid scintillation count-
ing. The proliferation of cells was measured as counts per
minute (mean ± SEM of triplicate values) after subtracting
values of responder T cell cultures alone.
Anergy assay to determine the activation status of the CD4 
T cells in the co-culture with VA-treated DCs
The anergy assay was performed according to a modified
protocol originally described by Steinbrink et al [27].
Briefly, four-day old DCs were treated for 48 hrs with VA
Qu Spez (15 μg/ml) or untreated or TNFα (15 ng/ml).
Responder CD4+ T cells were then co-cultured during the
first incubation at a density of 105 cells with 104 DC for 72
hrs. Then, T cells from the co-cultures were isolated by
using CD4+ beads (Miltenyl Biotech) and rested for 24 hrs
in the culture medium containing 2 U/ml IL-2. Subse-
quently, CD4+ T cells were re-stimulated with DCs gener-
ated from the same donor as that used for the first
stimulation and have undergone similar VA Qu Spez
treatment. After 48 hrs, the cells were pulsed for 16 h with
0.5  μCi (0.037 MBq) of (3H)thymidine. Radioactive
incorporation was measured by standard liquid scintilla-
tion counting. The proliferation of cells was measured as
counts per minute (mean ± SEM of triplicate values). Tests
were conducted in triplicates. Additionally, the levels of
cytokines TNF-α and IFNγ in the co-culture were analysed.
Activation of melanoma specific cytotoxic T cell (CTL) 
clones by VA Qu Spez-treated DCs
The melan-A-specific CTL clone M77-80 that was derived
from tumor infiltrating lymphocytes of melanoma patient
M77 is a kind gift from Dr. Nathalie Labarriere and Dr.
Francine Jotereau [28,29]. The VA Qu Spez-treated DCs
from HLA matched donor (HLA-A2, 104/well/200  μl
RPMI 1640 medium supplemented with 10% AB serum)
were cultured overnight with M77 CTLs (105) in 96 well
round-bottomed plates along with the MART-1 peptide (1
μM) and 25 IU/mL rh IL-2. The activation of M77-80 was
analyzed by measuring IFNγ and TNFα in the cell free-
supernatants.
Analysis of cytokines
Cytokines in the cell-free culture supernatant were quan-
tified using BD CBA Human Inflammation kit and
Human Th1/Th2 kits (BD Biosciences, France).
Statistical analysis
Statistical significance was determined using the Mann-
Whitney U test.
Results
VA Qu Spez enhances the expression of antigen presenting 
and co-stimulatory molecules on human DCs
We initially characterized the effect of VA Qu Spez on the
phenotype of human DCs. Four-day old immature DCs
were treated with VA preparations for 48 hrs and cells
were analyzed for the expression of various surface mole-
cules (Figure 1). We have used DCs treated with 15 ng/ml
of TNF-α as control in addition to the DCs that were left
untreated. VA Qu Spez enhanced the expression by DCs of
co-stimulatory molecules CD80 and CD86 (Figure 1) in
dose-dependent manner. The expression of CD80 on DCs
by 15 μg/ml concentration of VA Qu Spez (81.74 ± 2.3%
population and 1632.8 ± 152 mean fluorescence inten-
sity, MFI) was comparable to the DCs treated with TNF-α
(84.93 ± 1.1% and 1644.25 ± 195.4 MFI). In addition, Qu
Spez also significantly enhanced the percentage expres-
sion CD86 in a dose-dependent manner (Figure 1). How-
ever, the expression of HLA-DR, CD40 and CD83 were
either unaltered or marginally increased (data not
shown).
VA Qu Spez induces the secretion of pro-inflammatory 
cytokines IL-6 and IL-8 by DCs
In addition to co-stimulatory molecules, DC-derived
cytokines play a crucial role in priming T-cell response.
We therefore analyzed whether the maturation process of
DCs induced by VA Qu Spez is associated with the secre-
tion of pro-inflammatory cytokines such as IL-6 and IL-8.
The control DCs secreted 86.02 ± 23.3 pg/ml of IL-8 and
11.55 ± 6.28 pg/ml of IL-6 (n = 5 donors). However, as
shown in Figure 2, VA Qu Spez significantly stimulatedBMC Cancer 2008, 8:161 http://www.biomedcentral.com/1471-2407/8/161
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the secretion of IL-8 (308.052 ± 48.60 pg/ml) and IL-6
(54.97 ± 41.27 pg/ml) by DCs. Together these results indi-
cate that in addition to stimulating the expression of co-
stimulatory molecules on DCs, VA Qu Spez induce the
secretion of pro-inflammatory cytokines.
VA Qu Spez-treated DCs stimulate T cell proliferation
A major function of DCs is their ability to trigger the acti-
vation and proliferation of T cells. We thus examined
whether maturation of DCs induced by VA Qu Spez is
reflected in their capacity to stimulate CD4+ T cells in an
allogeneic MLR. As shown in Figure 3, VA Qu Spez-treated
DCs, stimulated the proliferation of CD4+ T cells in a
dose-dependent manner. The extent of CD4+ T cell prolif-
DCs treated with VA Qu Spez show an increased expression  of co-stimulatory molecules CD80 and CD86 Figure 1
DCs treated with VA Qu Spez show an increased 
expression of co-stimulatory molecules CD80 and 
CD86. The 4-day-old DCs (0.5 × 106) were treated with 
medium alone (Control) or with 15 ng/ml TNF-α or with 5, 
10 and 15 μg/ml of VA Qu Spez for 48 hours. The expression 
of CD80 (A and B) and CD86 (A and C) was analysed by 
flow cytometry (BD LSRII). Panel A shows the % of DCs pos-
itive for CD80 (open bars) and CD86 (filled bars), while 
mean fluorescence intensities were presented in Panels B and 
C. Data are presented as mean ± SEM from from five to six 
independent donors. Statistical significance (*, p < 0.05) as 
analysed by Mann-Whitney test is indicated.
DCs treated with VA Qu Spez show an increased secretion  of inflammatory cytokines IL-8 and IL-6 Figure 2
DCs treated with VA Qu Spez show an increased 
secretion of inflammatory cytokines IL-8 and IL-6. 
The 4-day-old DCs (0.5 × 106) were treated with medium 
alone (Control) or with 15 ng/ml TNF-α or with 5, 10 and 15 
μg/ml of VA Qu Spez for 48 hours. The secretion (pg/ml) of 
IL-8 (Panel A) and IL-6 (Panel B) in cell free supernatants 
were analysed by cytokine bead array assay. Data are pre-
sented as mean ± SEM from five to six independent donors. 
Statistical significance (*, p < 0.05) as analysed by Mann-Whit-
ney test is indicated.BMC Cancer 2008, 8:161 http://www.biomedcentral.com/1471-2407/8/161
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eration induced by VA Qu Spez-treated DCs was signifi-
cant at DC-T cell ratios of 1:10 and 1:20.
VA Qu Spez-treated DCs do not induce anergy of CD4+ T 
cells
We performed anergy assay to determine the activation
status of the CD4 T cells in the co-culture with VA Qu
Spez-treated DCs. As shown in Figure 4a, during first cycle
of CD4+ T cell stimulation in a MLR (day 0–day 7), VA Qu
Spez-treated DCs (81920 ± 9070 cpm) show similar abil-
ity to stimulate the proliferation of CD4+ T cells as com-
pared to TNF-α treated DCs (87439 ± 3910 cpm).
Interestingly, CD4+ T cells that were re-stimulated/chal-
lenged during second cycle of stimulation with VA Qu
Spez-treated DCs show increased proliferation (202276 ±
2052 cpm) as compared to the control DCs (76236 ±
4436 cpm) and TNF-α treated DCs (154341 ± 3224 cpm).
To further confirm that VA Qu Spez-treated DCs do not
impart CD4+T cell anergy, we analysed for the secretion of
T cell cytokines TNF-α and IFNγ in the DC-CD4+T cell co-
cultures. As shown in Figure 4b, CD4+ T cells that were re-
stimulated/challenged during second cycle of stimulation
with VA Qu Spez-treated DCs show increased secretion of
above cytokines as compared to control DCs. These results
suggest that maturation and activation of DCs induced by
VA Qu Spez have functional repercussion on T cell activa-
tion and not T cell anergy.
VA Qu Spez-treated DCs stimulate melanoma specific 
M77-80 CTL clone
Since, VA preparations have been used as a complimen-
tary therapy in cancer we examined whether VA Qu Spez-
stimulated DCs facilitate anti-tumoral T cell responses.
Therefore, HLA-matched VA Qu Spez-treated DCs were
co-cultured with Melan-A/MART-1 specific M77-80 CTL
clone (Figure 5). Strikingly, VA Qu Spez-treated DCs acti-
vated tumor antigen specific CTL clone as analyzed by the
secretion of cytokines TNF-α and IFNγ.
Discussion
Although VA preparations are widely used in clinical prac-
tice and cancer therapy, their mechanisms of action are yet
to be fully understood. In our previous studies, we have
shown that in addition to cytotoxic properties, VA prepa-
rations have immunostimulatory effects that facilitate
tumor regression in experimental models [13]. However,
to mount an effective anti-tumoral immune response, an
increased expression of co-stimulatory molecules on the
DCs, the sentinels of the immune system, accompanied
by an enhanced secretion of pro-inflammatory cytokines
that culminates in T cell proliferation is necessary.
DCs found within the tumor microenvironment are
found to have a relatively immature phenotype character-
ized by low levels CD86, and surface HLA-DR expression
and inability to produce pro-inflammatory cytokine
[30,31]. Clinical studies with mistletoe lectins have
shown that VA preparations stimulate the cytokine secre-
tion and function of monocytes, the precursors of DCs
[32]. The previous studies by Stein et al demonstrated that
mistletoe extract and their isolated components influ-
ences the maturation of DC with an increased expression
of co-stimulatory and antigen presenting molecules
[33,34]. Furthermore, we found that the up-regulation of
these molecules is accompanied by the induction of
inflammatory cytokines by the VA preparations and stim-
ulation of tumor specific T cells. Together these results
suggest that induction of maturation and activation of
human DCs is one of the mechanisms underlying the ben-
eficial effect of VA preparations as complimentary therapy
in cancer.
Previously, it has been demonstrated that VA lectin
induces the gene expression of IL-1 alpha, IL-1 beta, IL-6,
TNF-α, IFN-γ and GM-CSF from PBMC [35]. A recent clin-
ical study has shown that the CD14+ monocytes from
multiple myeloma patients could be induced to differen-
tiate into functional DCs by culturing them with the
cytokine cocktail consisting of GM-CSF, IL-4, IL-6, TNF-α
VA Qu Spez-treated DCs stimulate the proliferation of allo- geneic CD4+ T cells Figure 3
VA Qu Spez-treated DCs stimulate the proliferation 
of allogeneic CD4+ T cells. The 4-day-old DCs (0.5 × 
106) were treated with medium alone (Control) or with 15 
ng/ml TNF-α or with 5, 10 and 15 μg/ml of VA Qu Spez for 
48 hours. After 48 hr treatments, DCs were co-cultured 
with the allogeneic CD4+ T cells at different ratios in a 
round bottom 96-welled plate. After 4 days of co-culture, 
the cells were pulsed overnight with 0.5 μCi (0.037 MBq) of 
(3H)thymidine to quantify T-cell proliferation. Radioactive 
incorporation was measured by standard liquid scintillation 
counting, and the results were expressed as counts per 
minute (mean ± SEM of triplicate values). Statistical signifi-
cance (*, p < 0.05) as analysed by Mann-Whitney test is indi-
cated.BMC Cancer 2008, 8:161 http://www.biomedcentral.com/1471-2407/8/161
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and IL-1β for use in cancer immunotherapy [36]. Our data
demonstrates that VA Qu Spez-mediated maturation of
DCs and secretion of pro-inflammatory cytokines (IL-6
and IL-8) has repercussion on the stimulation of CD4+ T
cells and their cytokine secretion. It is interesting to note
that VA Qu Spez-treated DCs do not induce anergy of T
cells as shown by the induction of proliferation and the
secretion of TNF-α and IFNγ by the CD4+ T cells. Thus,
induction of DC-cytokines and T cell cytokines by VA Qu
Spez represents a critical determinant in the development
of effective innate immune responses against the tumor
cells [37].
CD8+ cytotoxic T lymphocytes (CTLs) are critical for the
elimination of tumor. Thus, therapies aimed at expansion
of CTLs and their functions holds the key in mounting an
effective anti-tumor immune response. The ability of the
CTLs to recognize the processed peptides derived from the
cellular genes, such as those encoding MART-1 or tyrosi-
nase in melanoma, led to the recognition that protective
immune responses are often directed towards tumor-asso-
ciated, rather than tumor-specific, antigens [28,29]. Using
Melan-A/MART-1 specific M77-80 CTL clone, we have
VA Qu Spez-treated DCs do not induce CD4+ T cell anergy Figure 4
VA Qu Spez-treated DCs do not induce CD4+ T cell 
anergy. The 4-day-old DCs (0.5 × 106) were treated with 
medium alone (Control) or with 15 ng/ml TNF-α or with 15 
μg/ml of VA Qu Spez for 48 hours. The DCs were then co-
cultured with the allogeneic CD4+ T cells at 1:10 ratio in a 
round bottom 96-welled plate for 72 hrs for the first cycle of 
stimulation. The T cells from in the co-cultures were then 
purified and were rested for 24 hrs in the presence of 2 IU/
ml of IL-2. These CD4+ T cells were then subjected for sec-
ond cycle of stimulation with similiarly treated DCs from 
same donor. After 48 hrs of co-culture, the cells were pulsed 
overnight with 0.5 μCi (0.037 MBq) of (3H)thymidine to 
quantify T-cell proliferation (Panel A, filled bars). Radioactive 
incorporation was measured by standard liquid scintillation 
counting, and the results were expressed as counts per 
minute (mean ± SEM of triplicate values). DC-T cell co-cul-
tures of first cycle of stimulation that were maintained for 7 
days were used for the comparison (Panel A, open bars). Sta-
tistical significance (*, p < 0.05) as analysed by Mann-Whitney 
test is indicated. The level of T cell cytokines IFNγ (Panels B 
and D) and TNF-α (Panels C and E) in the cell-free superna-
tants from above cultures were analysed by cytokine bead 
array. Panels B and C indicate the level of cytokines in DC-T 
cell co-cultures of first cycle of stimulation that were main-
tained for 7 days. Panels D and E present the level of 
cytokines in DC-T cell co-cultures of second cycle of stimu-
lation.
VA Qu Spez-treated DCs stimulate melanoma specific M77- 80 CTL clone Figure 5
VA Qu Spez-treated DCs stimulate melanoma spe-
cific M77-80 CTL clone. The 4-day-old DCs (0.5 × 106) 
from HLA-A2 donor were treated with medium alone (Con-
trol) or with 15 ng/ml TNF-α or with 15 μg/ml of VA Qu 
Spez for 48 hours. The DCs (104/well/200 μl medium) were 
then cultured overnight with M77-80 CTLs (105) in 96 well 
round-bottomed plates along with the MART-1 peptide (1 
μM) and 25 IU/mL rh IL-2. The activation of M77-80 was ana-
lyzed by measuring TNFα (Panel A) and IFNγ (Panel B) in the 
cell free-supernatants by using cytokine bead array.BMC Cancer 2008, 8:161 http://www.biomedcentral.com/1471-2407/8/161
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shown that DCs "educated" by VA Qu Spez can mount an
anti-tumoral immune response as suggested by the
increased levels of secretion of TNF-α and IFNγ by the
CTLs in the co-culture. Further studies on the effect of the
VA preparations on the DCs that have been subjected to
inactivation by tumor factors, may provide strategies in
dissecting the stimulatory effects of the VA preparations
on the DCs.
Conclusion
VA preparations are known to have cytotoxic properties
towards the tumor cells. They are also known to improve
the quality of life in the cancer patients. However, the
mechanisms by which VA preparations stimulate the
immune system and exert beneficial effects in patients are
not yet clear. We have demonstrated the role of the VA
preparations in stimulating the DCs with implications in
the induction of anti-tumor immunity. However, these in
vitro results need to be validated further in the context of
clinical studies. The elucidation of immunostimulatory
mechanisms of VA preparations is critical in understand-
ing their role as complimentary therapy in cancer.
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